Cargando…
Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reporte...
Autores principales: | Janssen, R. A., Sleijfer, D. T., Heijn, A. A., Mulder, N. H., The, T. H., de Leij, L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978045/ https://www.ncbi.nlm.nih.gov/pubmed/1457361 |
Ejemplares similares
-
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
por: Martens, A., et al.
Publicado: (1993) -
Prolonged continuous infusion of low-dose rIL-2.
por: Janssen, R. A., et al.
Publicado: (1994) -
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
por: Kroesen, B. J., et al.
Publicado: (1994) -
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
por: Geertsen, P F, et al.
Publicado: (2004) -
Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.
por: Janssen, R. A., et al.
Publicado: (1995)